Explore more about: RADx Tech

ANP Technologies announced on Monday that its SARS-CoV-2 rapid antigen test has received Emergency Use Authorization from the US Food and Drug Administration.

A new $13.3 million contract from the NIH's Rapid Acceleration of Diagnostics (RADx) initiative will enable the David Geffen School of Medicine at UCLA to expand its capacity to process COVID-19 tests.

In a study that compares rapid antigen and laboratory PCR approaches for COVID-19 serial screening, researchers affiliated with the NIH RADx initiative reported results from 43 people infected with the virus.

The National Institutes of Health (NIH) today announced three new contracts and one new award to an existing contract for scale-up and manufacturing of novel COVID-19 testing technologies.

NIH has awarded four additional contracts for the development and scaled-up manufacturing of new COVID-19 diagnostic testing technologies through its Rapid Acceleration of Diagnostics Tech (RADx) initiative. The awards total $29.3 million and will help increase testing capacity for COVID-19.

An NIH-funded research team has launched a study to assess performance and usability of a smartphone app paired with the Quidel QuickVue At-Home COVID-19 Test, which received FDA emergency use authorization for use with a prescription.

NIH is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s RADx initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests.

In a paper in the New England Journal of Medicine, scientific leaders from the National Institutes of Health set forth a framework to increase significantly the number, quality and type of daily tests for detecting SARS-CoV-2, the virus that causes COVID-19, and help reduce inequities for underserved populations that have been disproportionally affected by the disease.